secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2022-12-02T23:59:59+00:00
Accession:  0000950170-22-025995
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta announces Dec 5 call to review updated NKX019 clinical data; no data in filing
--------------------------------------------------------------------------------

- Conference call scheduled for December 5, 2022 at 8:00 a.m. ET to review updated clinical data from NKX019.
- NKX019 is a CD19-directed CAR NK cell therapy for cancer; no specific data provided in the press release.
- Slides will be posted on Nkarta's website; a replay will be available for 4 weeks.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000095017022025995/0000950170-22-025995-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000095017022025995/nktx-20221202.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-025995

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer